WHAT IS CLAIMED IS:

1. A method for formulating a deaggregated polyene antibiotic, said method comprising the steps of :

   (a) dissolving a polyene antibiotic and a poly(ethylene glycol)-phospholipid in a solvent to produce a solution;

   (b) evaporating the solvent from the solution of step (a) under conditions of temperature from 26°C to 40°C and conditions of pressure from 100 mm to 300 mm mercury to produce a drug-polymer film;

   (c) adding water at a temperature from 25°C to 80°C to the drug-polymer film of step (b) and mixing vigorously,

   whereby micelles comprising the polyene antibiotic and poly(ethylene glycol)-phospholipid are formed.

2. The method of claim 1 wherein the poly(ethylene glycol)-phospholipid is monomethoxy poly(ethylene glycol)-1,2-di-stearoyl-phosphatidyl ethanolamine.

3. The method of claim 1 wherein the polyene antibiotic is Amphotericin B (AmB).

4. The method of claim 1 wherein the solvent is methanol or chloroform:methanol (1:2).

5. The method of claim 4 wherein the conditions for evaporating the solvent are 40°C and 300 mm mercury.

6. The method of claim 3 wherein in step (c) water is added at a temperature from 40°C to 75°C.

7. The method of claim 2 wherein the molecular weight of the poly(ethylene glycol)-1,2-di-stearoyl-phosphatidyl ethanolamine is about 5000 to about 12,000.

8. The method of claim 3 wherein the poly(ethylene glycol)-phospholipid is monomethoxy poly(ethylene glycol)-1,2-di-stearoyl-phosphatidyl ethanolamine and the molar ratio of AmB to poly(ethylene glycol)-1,2-di-stearoyl-phosphatidyl ethanolamine to AmB is from about 0.75:1 to about 10:1.

9. The method of claim 8 wherein the molar ratio of poly(ethylene glycol)-1,2-di-stearoyl-phosphatidyl ethanolamine to AmB is from 1:1 to 3:1.

10. The method of claim 9 wherein the molar ratio of poly(ethylene glycol)-1,2-di-stearoyl-phosphatidyl ethanolamine to AmB is 1:1 to 1.5:1.

11. The method of claim 1 further comprising the step of freeze-drying the micelles after step (c).

12. A composition comprising micelles consisting essentially of Amphotericin B (AmB) and poly(ethylene glycol)-1,2-di-stearoyl-phosphatidyl ethanolamine (mPEG-DSPE) in a molar ratio of mPEG-DSPE:AmB of from 1:1 to 3:1.

13. The composition of claim 12 further comprising a pharmaceutically acceptable carrier.

14. The composition of claim 13 wherein the pharmaceutically acceptable carrier is a dextrose solution.